Literature DB >> 9014834

Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro.

R Hatton1, M Stimpel, T J Chambers.   

Abstract

During bone resorption, osteoclasts are closely associated with endothelial cells. The latter are able to produce several agents that regulate bone resorption. In view of the increasing evidence that angiotensin II, which can be generated by endothelial cells, has actions outside the traditional renin-angiotensin system, we tested the effect of angiotensin II on bone resorption Angiotensin II showed no effect either on osteoclast formation or on bone resorption by isolated osteoclasts. However, in co-cultures of osteoclasts with calvarial or MC3T3-E1 osteoblastic cells, and in osteoclastic cultures co-cultured with other bone cells obtained by prolonged sedimentation, angiotensin II stimulated bone resorption to a similar degree to that observed with 1,25(OH)2 vitamin D3. Stimulation of resorption was noted at concentrations of 10(-7) M and above. We found that angiotensin I also stimulated bone resorption in co-cultures of osteoclasts with osteoblastic cells, and that this action was inhibited by inhibitors of angiotensin-converting enzyme. These results identify angiotensin I and II as potent stimulators of osteoclastic bone resorption, and raise the possibility that bone might contain a tissue-renin-angiotensin system that might play a role in the regulation of bone resorption.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9014834     DOI: 10.1677/joe.0.1520005

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  34 in total

1.  Long-term use of angiotensin-converting enzyme inhibitors protects against bone loss in African-American elderly men.

Authors:  Nahid Rianon; Catherine G Ambrose; Hannah Pervin; Melissa Garcia; Scherezade K Mama; Ann V Schwartz; Brendan Lee; Tamara Harris
Journal:  Arch Osteoporos       Date:  2017-10-28       Impact factor: 2.617

2.  Role of reactive oxygen species in angiotensin II: induced receptor activator of nuclear factor-κB ligand expression in mouse osteoblastic cells.

Authors:  Yanqiu Zhang; Yongtao Zhang; Jianqiang Kou; Chunsheng Wang; Kunzheng Wang
Journal:  Mol Cell Biochem       Date:  2014-07-26       Impact factor: 3.396

Review 3.  Systemic hypertension in postmenopausal women: a clinical approach.

Authors:  Enrique Z Fisman; Alexander Tenenbaum; Amos Pines
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

Review 4.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

5.  Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts.

Authors:  Yu Yu Liu; Wei Min Yao; Tie Wu; Bi Lian Xu; Fang Chen; Liao Cui
Journal:  J Bone Miner Metab       Date:  2010-08-06       Impact factor: 2.626

6.  Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation - role of a local renin-angiotensin system.

Authors:  P Garcia; S Schwenzer; J E Slotta; C Scheuer; A E Tami; J H Holstein; T Histing; M Burkhardt; T Pohlemann; M D Menger
Journal:  Br J Pharmacol       Date:  2010-03-05       Impact factor: 8.739

7.  Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?

Authors:  T Kwok; J Leung; Y F Zhang; D Bauer; K E Ensrud; E Barrett-Connor; P C Leung
Journal:  Osteoporos Int       Date:  2011-11-12       Impact factor: 4.507

8.  Association of Circulating Renin and Aldosterone With Osteocalcin and Bone Mineral Density in African Ancestry Families.

Authors:  Allison L Kuipers; Candace M Kammerer; J Howard Pratt; Clareann H Bunker; Victor W Wheeler; Alan L Patrick; Joseph M Zmuda
Journal:  Hypertension       Date:  2016-03-14       Impact factor: 10.190

9.  The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese.

Authors:  Ya-Feng Zhang; Ling Qin; Ping-Chung Leung; Timothy C Y Kwok
Journal:  J Bone Miner Metab       Date:  2012-06-29       Impact factor: 2.626

Review 10.  Moexipril. A review of its use in the management of essential hypertension.

Authors:  R N Brogden; L R Wiseman
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.